154 related articles for article (PubMed ID: 28134073)
1. Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice.
Leon L; Rodriguez-Rodriguez L; Freites D; Arietti L; Morado I; Vadillo C; Lamas JR; Fernandez B; Jover JA; Abasolo L
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):165-170. PubMed ID: 28134073
[TBL] [Abstract][Full Text] [Related]
2. Treatment with methotrexate and risk of relapses in patients with giant cell arteritis in clinical practice.
Leon L; Rodriguez-Rodriguez L; Morado I; Rosales Z; Vadillo C; Freites D; Macarron P; Fernandez-Gutierrez B; Blanco M; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):121-128. PubMed ID: 29303708
[TBL] [Abstract][Full Text] [Related]
3. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis.
Muratore F; Pipitone N; Hunder GG; Salvarani C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S86-92. PubMed ID: 24129145
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.
Mahr AD; Jover JA; Spiera RF; Hernández-García C; Fernández-Gutiérrez B; Lavalley MP; Merkel PA
Arthritis Rheum; 2007 Aug; 56(8):2789-97. PubMed ID: 17665429
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study.
Koster MJ; Yeruva K; Crowson CS; Muratore F; Labarca C; Warrington KJ
J Rheumatol; 2019 May; 46(5):501-508. PubMed ID: 30647171
[TBL] [Abstract][Full Text] [Related]
7. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice.
Varatharajan N; Lim IG; Anandacoomarasamy A; Russo R; Byth K; Spencer DG; Manolios N; Howe GB
Intern Med J; 2009 Apr; 39(4):228-36. PubMed ID: 19402861
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.
Hoffman GS; Cid MC; Hellmann DB; Guillevin L; Stone JH; Schousboe J; Cohen P; Calabrese LH; Dickler H; Merkel PA; Fortin P; Flynn JA; Locker GA; Easley KA; Schned E; Hunder GG; Sneller MC; Tuggle C; Swanson H; Hernández-Rodríguez J; Lopez-Soto A; Bork D; Hoffman DB; Kalunian K; Klashman D; Wilke WS; Scheetz RJ; Mandell BF; Fessler BJ; Kosmorsky G; Prayson R; Luqmani RA; Nuki G; McRorie E; Sherrer Y; Baca S; Walsh B; Ferland D; Soubrier M; Choi HK; Gross W; Segal AM; Ludivico C; Puechal X;
Arthritis Rheum; 2002 May; 46(5):1309-18. PubMed ID: 12115238
[TBL] [Abstract][Full Text] [Related]
10. European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis.
Kopylov U; Katsanos KH; van der Woude CJ; Karmiris K; Hernandez V; Odes S; Papamichael K; Koutroubakis IE; Bojic D; Kaimakliotis I; Fiorino G; Papageorgiou N; Pineda JR; Strongili K; Sanroman L; Mantzaris GJ; Jojic N; Paspatis G; Christodoulou DK; Ben-Horin S; Tsianos EV
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):802-6. PubMed ID: 26894634
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres.
Loock J; Henes J; Kötter I; Witte T; Lamprecht P; Schirmer M; Gross WL
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S70-6. PubMed ID: 22640650
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis.
Sun Y; Ma L; Ma L; Kong X; Chen H; Lv P; Lin J; Liu H; Yan Y; Ji Z; Yang C; Dai S; Wan W; Zou Y; Jin X; Jiang L
Rheumatol Int; 2017 Dec; 37(12):2019-2026. PubMed ID: 29030659
[TBL] [Abstract][Full Text] [Related]
13. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice.
Leon L; Rodriguez-Rodriguez L; Rosales Z; Gomez A; Lamas JR; Pato E; Jover JA; Abasolo L
Scand J Rheumatol; 2016 Nov; 45(6):456-460. PubMed ID: 27115843
[TBL] [Abstract][Full Text] [Related]
14. Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis.
Rodriguez-Rodriguez L; Jover-Jover JA; Fontsere O; Peña-Blanco RC; León L; Fernández-Gutierrez B; Abásolo L
Scand J Rheumatol; 2013; 42(6):433-6. PubMed ID: 23742043
[TBL] [Abstract][Full Text] [Related]
15. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
[TBL] [Abstract][Full Text] [Related]
16. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis.
Nagashima M; Matsuoka T; Saitoh K; Koyama T; Kikuchi O; Yoshino S
Clin Exp Rheumatol; 2006; 24(3):260-7. PubMed ID: 16870092
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of methotrexate in a real-life monocentric cohort of patients with giant cell arteritis.
Lavergne A; Dumont A; Deshayes S; Boutemy J; Maigné G; Silva NM; Nguyen A; Gallou S; Philip R; Aouba A; de Boysson H
Semin Arthritis Rheum; 2023 Jun; 60():152192. PubMed ID: 36963127
[TBL] [Abstract][Full Text] [Related]
18. Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project.
Uribarri M; Ruiz-Larrañaga O; Arteta D; Hernández L; Alcaro MC; Martínez A; Escorza-Treviño S; Estonba A; Migliorini P; Czirják L; del Amo J
Clin Exp Rheumatol; 2015; 33(5):699-705. PubMed ID: 26314492
[TBL] [Abstract][Full Text] [Related]
19. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate.
Hoffman GS; Leavitt RY; Kerr GS; Rottem M; Sneller MC; Fauci AS
Arthritis Rheum; 1994 Apr; 37(4):578-82. PubMed ID: 7908520
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive Drug Discontinuation in Noninfectious Uveitis From Real-Life Clinical Practice: A Survival Analysis.
Abásolo L; Rosales Z; Díaz-Valle D; Gómez-Gómez A; Peña-Blanco RC; Prieto-García Á; Benítez-Del-Castillo JM; Pato E; García-Feijoo J; Fernández-Gutiérrez B; Rodriguez-Rodriguez L
Am J Ophthalmol; 2016 Sep; 169():1-8. PubMed ID: 27296486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
